Skip to main content
Erschienen in: Journal of Clinical Immunology 1/2008

01.05.2008

Understanding Systemic Lupus Erythematosus Physiopathology in the Light of Primary Immunodeficiencies

verfasst von: Magda Carneiro-Sampaio, Bernadete Lourdes Liphaus, Adriana Almeida Jesus, Clovis Artur A. Silva, João Bosco Oliveira, Maria Helena Kiss

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Associations between systemic lupus erythematosus (SLE) and primary immunodeficiencies (PIDs) were analyzed to gain insight into the physiopathology of SLE. Some PIDs have been consistently associated with SLE or lupus-like manifestations: (a) homozygous deficiencies of the early components of the classical complement pathway in the following decreasing order: in C1q, 93% of affected patients developed SLE; in C4, 75%; in C1r/s, 57%; and in C2, up to 25%; (b) female carriers of X-linked chronic granulomatous disease allele; and (c) IgA deficiency, present in around 5% of juvenile SLE.

Discussion

In the first two groups, disturbances of cellular waste-disposal have been proposed as the main mechanisms of pathogenesis. On the other hand and very interestingly, there are PIDs systematically associated with several autoimmune manifestations in which SLE has not been described, such as autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), immunedysregulation polyendocrinopathy enteropathy X-linked (IPEX), and autoimmune lymphoproliferative syndrome (ALPS), suggesting that mechanisms considered as critical players for induction and maintenance of tolerance to autoantigens, such as (1) AIRE-mediated thymic negative selection of lymphocytes, (2) Foxp3+ regulatory T cell-mediated peripheral tolerance, and (3) deletion of auto-reactive lymphocytes by Fas-mediated apoptosis, could not be relevant in SLE physiopathology. The non-description of SLE and neither the most characteristic SLE clinical features among patients with agammaglobulinemia are also interesting observations, which reinforce the essential role of B lymphocytes and antibodies for SLE pathogenesis.

Conclusion

Therefore, monogenic PIDs represent unique and not fully explored human models for unraveling components of the conundrum represented by the physiopathology of SLE, a prototypical polygenic disease.
Literatur
1.
Zurück zum Zitat Geha RS, Notarangelo L, Casanova J-L, Chapel H, Conley ME, Fischer A, Hammarström L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007;120:776–94.PubMedCrossRef Geha RS, Notarangelo L, Casanova J-L, Chapel H, Conley ME, Fischer A, Hammarström L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007;120:776–94.PubMedCrossRef
2.
Zurück zum Zitat Carneiro-Sampaio M, Coutinho A. Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies. Adv Immunol 2007;95:51–82.PubMedCrossRef Carneiro-Sampaio M, Coutinho A. Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies. Adv Immunol 2007;95:51–82.PubMedCrossRef
3.
Zurück zum Zitat Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology 1999;42:47–52.PubMedCrossRef Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology 1999;42:47–52.PubMedCrossRef
4.
Zurück zum Zitat Pickering MC, Botto M, Taylor PR, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227–34.PubMed Pickering MC, Botto M, Taylor PR, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227–34.PubMed
5.
Zurück zum Zitat Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431–56.PubMedCrossRef Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431–56.PubMedCrossRef
6.
Zurück zum Zitat Sjöholm AG, Jönsson G, Braconier JH, Sturfelt G, Truedsson L. Complement deficiency and disease: an update. Mol Immunol 2006;43:78–85.PubMedCrossRef Sjöholm AG, Jönsson G, Braconier JH, Sturfelt G, Truedsson L. Complement deficiency and disease: an update. Mol Immunol 2006;43:78–85.PubMedCrossRef
7.
Zurück zum Zitat Koide M, Shirahama S, Tokura Y, Takigawa M, Hayakawa M, Furukawa F. Lupus erythematosus associated with C1 inhibitor deficiency. J Dermatol 2002;29:503–7.PubMed Koide M, Shirahama S, Tokura Y, Takigawa M, Hayakawa M, Furukawa F. Lupus erythematosus associated with C1 inhibitor deficiency. J Dermatol 2002;29:503–7.PubMed
8.
Zurück zum Zitat Kemper C, Chan AC, Green J, Brett KA, Murphy KM, Atkinson P. Activation of human CD4+cells with CD3 and CD466 induces a T-regulatory cell 1 phenotype. Nature 2003;42:388–92.CrossRef Kemper C, Chan AC, Green J, Brett KA, Murphy KM, Atkinson P. Activation of human CD4+cells with CD3 and CD466 induces a T-regulatory cell 1 phenotype. Nature 2003;42:388–92.CrossRef
9.
Zurück zum Zitat Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155–69.CrossRefPubMed Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155–69.CrossRefPubMed
10.
Zurück zum Zitat Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007;148:79–84.PubMed Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007;148:79–84.PubMed
11.
Zurück zum Zitat Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease. J Leukoc Biol 2003;73:591–9.PubMedCrossRef Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease. J Leukoc Biol 2003;73:591–9.PubMedCrossRef
12.
Zurück zum Zitat Sanford AN, Suriano AR, Herche D, Dietzmann K, Sullivan KE. Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus. Rheumatology 2006;45:178–81.PubMedCrossRef Sanford AN, Suriano AR, Herche D, Dietzmann K, Sullivan KE. Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus. Rheumatology 2006;45:178–81.PubMedCrossRef
13.
Zurück zum Zitat Liblau RS, Bach JF. Selective IgA deficiency and autoimmunity. Int Arch Allergy Immunol 1992;99:16–27.PubMedCrossRef Liblau RS, Bach JF. Selective IgA deficiency and autoimmunity. Int Arch Allergy Immunol 1992;99:16–27.PubMedCrossRef
14.
Zurück zum Zitat Rankin EC, Isenberg DA. IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Lupus 1997;6:390–4.PubMedCrossRef Rankin EC, Isenberg DA. IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Lupus 1997;6:390–4.PubMedCrossRef
15.
Zurück zum Zitat Cassidy JT, Kitson RK, Selby CL. Selective IgA deficiency in children and adults with systemic lupus erythematosus. Lupus 2007;16:647–50.PubMedCrossRef Cassidy JT, Kitson RK, Selby CL. Selective IgA deficiency in children and adults with systemic lupus erythematosus. Lupus 2007;16:647–50.PubMedCrossRef
16.
Zurück zum Zitat Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffié C, Hénin D, Benhamou M, Pretolani M, Blank U, Monteiro RC. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005;22:31–42.PubMed Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffié C, Hénin D, Benhamou M, Pretolani M, Blank U, Monteiro RC. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005;22:31–42.PubMed
17.
Zurück zum Zitat Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990;322:1829–36.PubMed Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990;322:1829–36.PubMed
18.
Zurück zum Zitat Betterle C, Greggio NA, Volpato M. Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998;83:1049–55.PubMedCrossRef Betterle C, Greggio NA, Volpato M. Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998;83:1049–55.PubMedCrossRef
19.
Zurück zum Zitat Perheentupä J. Extensive Clinical experience: autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy. J Clin Endocrinol Metab 2006;91:2843–50.PubMedCrossRef Perheentupä J. Extensive Clinical experience: autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy. J Clin Endocrinol Metab 2006;91:2843–50.PubMedCrossRef
20.
Zurück zum Zitat Perniola R, Falorni A, Clemente MG, Forini F, Accogli E, Lobreglio G. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED). Eur J Endocrinol 2000;143:497–503.PubMedCrossRef Perniola R, Falorni A, Clemente MG, Forini F, Accogli E, Lobreglio G. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED). Eur J Endocrinol 2000;143:497–503.PubMedCrossRef
21.
Zurück zum Zitat Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of immune dysregulation, polyendocrinopathy, and X-linked inheritance (IPEX), a syndrome. J Med Genet 2002;39:537–45.PubMedCrossRef Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of immune dysregulation, polyendocrinopathy, and X-linked inheritance (IPEX), a syndrome. J Med Genet 2002;39:537–45.PubMedCrossRef
22.
Zurück zum Zitat Ochs HD, Ziegler SF, Torgerson TR. FOXP3 acts as a rheostat of the immune response. Immunol Rev 2005;203:156–64.PubMedCrossRef Ochs HD, Ziegler SF, Torgerson TR. FOXP3 acts as a rheostat of the immune response. Immunol Rev 2005;203:156–64.PubMedCrossRef
23.
Zurück zum Zitat Torgerson T. Regulatory T cells in human autoimmune diseases. Springer Semin Immun 2006;28:63–76.CrossRef Torgerson T. Regulatory T cells in human autoimmune diseases. Springer Semin Immun 2006;28:63–76.CrossRef
24.
Zurück zum Zitat Oliveira JB, Fleisher T. Autoimmune lymproliferative syndrome. Curr Opin Allergy Clin Immunol, 2004;4:497–503.CrossRef Oliveira JB, Fleisher T. Autoimmune lymproliferative syndrome. Curr Opin Allergy Clin Immunol, 2004;4:497–503.CrossRef
25.
Zurück zum Zitat Oliveira JB, Bidère N, Niemela JE, Zheng L, Sakai K, Nix CP, Danner RL, Barb J, Munson PJ, Puck JM, Dale J, Straus SE, Fleisher TA, Lenardo MJ. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A 2007;104:8953–8.PubMedCrossRef Oliveira JB, Bidère N, Niemela JE, Zheng L, Sakai K, Nix CP, Danner RL, Barb J, Munson PJ, Puck JM, Dale J, Straus SE, Fleisher TA, Lenardo MJ. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A 2007;104:8953–8.PubMedCrossRef
26.
Zurück zum Zitat Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107–13.PubMedCrossRef Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107–13.PubMedCrossRef
27.
Zurück zum Zitat Liphaus BL, Kiss MH, Carrasco S, Goldenstein-Schainberg C. Increased Fas and Bcl-2 expression on peripheral cells from patients with active juvenile-onset systemic lupus erythematosus. J Rheum 2007;34:1580–4.PubMed Liphaus BL, Kiss MH, Carrasco S, Goldenstein-Schainberg C. Increased Fas and Bcl-2 expression on peripheral cells from patients with active juvenile-onset systemic lupus erythematosus. J Rheum 2007;34:1580–4.PubMed
28.
Zurück zum Zitat Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Italian Pediatric Group for XLA-AIEOP. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002;104:221–30.PubMedCrossRef Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Italian Pediatric Group for XLA-AIEOP. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002;104:221–30.PubMedCrossRef
29.
Zurück zum Zitat Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85:193–202.CrossRef Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85:193–202.CrossRef
30.
Zurück zum Zitat Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol 2006;118:201–8.PubMedCrossRef Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol 2006;118:201–8.PubMedCrossRef
31.
Zurück zum Zitat Fernandez-Castro M, Mellor-Pita S, Citores MJ, Muñoz P, Tutor-Ureta P, Silva L, Vargas JA, Yebra-Bango M, Andreu JL. Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum 2007;36:238–45.PubMedCrossRef Fernandez-Castro M, Mellor-Pita S, Citores MJ, Muñoz P, Tutor-Ureta P, Silva L, Vargas JA, Yebra-Bango M, Andreu JL. Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum 2007;36:238–45.PubMedCrossRef
32.
Zurück zum Zitat Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005;25:57–62.PubMedCrossRef Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005;25:57–62.PubMedCrossRef
33.
Zurück zum Zitat Glocker E, Ehl S, Grimbacher B. Common variable immunodeficiency in children. Curr Opin Pediatr 2007;19:685–92.PubMed Glocker E, Ehl S, Grimbacher B. Common variable immunodeficiency in children. Curr Opin Pediatr 2007;19:685–92.PubMed
34.
Zurück zum Zitat Salzer U, Maul-Pavicic A, Cunningham-Rundles C, Urschel S, Belohradsky BH, Litzman J, Holm A, et al. ICOS deficiency in patients with common variable immunodeficiency. Clin Immunol 2004;113:234–40.PubMedCrossRef Salzer U, Maul-Pavicic A, Cunningham-Rundles C, Urschel S, Belohradsky BH, Litzman J, Holm A, et al. ICOS deficiency in patients with common variable immunodeficiency. Clin Immunol 2004;113:234–40.PubMedCrossRef
35.
Zurück zum Zitat Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37:820–8.PubMedCrossRef Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37:820–8.PubMedCrossRef
36.
Zurück zum Zitat Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47–54.PubMedCrossRef Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47–54.PubMedCrossRef
37.
Zurück zum Zitat Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome. Medicine 2003;82:373–84.PubMedCrossRef Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome. Medicine 2003;82:373–84.PubMedCrossRef
38.
Zurück zum Zitat Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 2005;203:48–66.PubMedCrossRef Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 2005;203:48–66.PubMedCrossRef
39.
Zurück zum Zitat Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063–73.PubMedCrossRef Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063–73.PubMedCrossRef
40.
Zurück zum Zitat Durandy A, Notarangelo L, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev 2005;203:67–79.PubMedCrossRef Durandy A, Notarangelo L, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev 2005;203:67–79.PubMedCrossRef
41.
Zurück zum Zitat Melegari A, Mascia MT, Sandri G, Carbonieri A. Immunodeficiency and autoimmune phenomena in female hyper-IgM syndrome. Ann N Y Acad Sci 2007;1109:106–8.PubMedCrossRef Melegari A, Mascia MT, Sandri G, Carbonieri A. Immunodeficiency and autoimmune phenomena in female hyper-IgM syndrome. Ann N Y Acad Sci 2007;1109:106–8.PubMedCrossRef
42.
Zurück zum Zitat Shrinath M, Walter JH, Haeney M, Couriel JM, Lewis MA, Herrick AL. Prolidase deficiency and systemic lupus erythematosus. Arch Dis Child 1997;76:441–4.PubMedCrossRef Shrinath M, Walter JH, Haeney M, Couriel JM, Lewis MA, Herrick AL. Prolidase deficiency and systemic lupus erythematosus. Arch Dis Child 1997;76:441–4.PubMedCrossRef
43.
Zurück zum Zitat Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, Le Deist F, et al. Autoimmunity in Wiskott–Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003;111:e622–7.PubMedCrossRef Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, Le Deist F, et al. Autoimmunity in Wiskott–Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003;111:e622–7.PubMedCrossRef
44.
Zurück zum Zitat Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott–Aldrich syndrome. J Pediatr 1994;125:876–85.PubMedCrossRef Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott–Aldrich syndrome. J Pediatr 1994;125:876–85.PubMedCrossRef
45.
Zurück zum Zitat Rosenzweig SD, Holland SM. Defects in the interferon-γ and interleukin 12 pathways. Immunol Rev 2005;3:38–47.CrossRef Rosenzweig SD, Holland SM. Defects in the interferon-γ and interleukin 12 pathways. Immunol Rev 2005;3:38–47.CrossRef
46.
Zurück zum Zitat Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet. 2007;370:1443–52.PubMedCrossRef Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet. 2007;370:1443–52.PubMedCrossRef
47.
Zurück zum Zitat de Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AEGK. Neutrophil FcγRIIIb deficiency, nature and clinical consequences: a study of 21 individuals from 14 families. Blood 1995;86:2403–13.PubMed de Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AEGK. Neutrophil FcγRIIIb deficiency, nature and clinical consequences: a study of 21 individuals from 14 families. Blood 1995;86:2403–13.PubMed
Metadaten
Titel
Understanding Systemic Lupus Erythematosus Physiopathology in the Light of Primary Immunodeficiencies
verfasst von
Magda Carneiro-Sampaio
Bernadete Lourdes Liphaus
Adriana Almeida Jesus
Clovis Artur A. Silva
João Bosco Oliveira
Maria Helena Kiss
Publikationsdatum
01.05.2008
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe Sonderheft 1/2008
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-008-9187-2

Weitere Artikel der Sonderheft 1/2008

Journal of Clinical Immunology 1/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.